Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 113, Issue 12, Pages 1687-1693
Publisher
Springer Nature
Online
2015-12-04
DOI
10.1038/bjc.2015.407
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study†
- (2015) B. J. Monk et al. ANNALS OF ONCOLOGY
- Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations
- (2014) F. Ricci et al. CANCER RESEARCH
- Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin
- (2013) Andrés Poveda et al. CANCER TREATMENT REVIEWS
- Comparison ofin vitroandin vivobiological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)
- (2013) Michela Romano et al. INTERNATIONAL JOURNAL OF CANCER
- Evidence for different mechanisms of ‘unhooking’ for melphalan and cisplatin-induced DNA interstrand cross-links in vitroand in clinical acquired resistant tumour samples
- (2012) Victoria J Spanswick et al. BMC CANCER
- Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents
- (2011) S. Uboldi et al. INTERNATIONAL JOURNAL OF CANCER
- Guidelines for the welfare and use of animals in cancer research
- (2010) P Workman et al. BRITISH JOURNAL OF CANCER
- A Review of Trabectedin (ET-743): A Unique Mechanism of Action
- (2010) Maurizio D'Incalci et al. MOLECULAR CANCER THERAPEUTICS
- H2AX: functional roles and potential applications
- (2009) Jennifer S. Dickey et al. CHROMOSOMA
- Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
- (2009) C. Forni et al. MOLECULAR CANCER THERAPEUTICS
- ZNF93 Increases Resistance to ET-743 (Trabectedin; Yondelis®) and PM00104 (Zalypsis®) in Human Cancer Cell Lines
- (2009) Zhenfeng Duan et al. PLoS One
- Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy
- (2008) P.H. Clingen et al. BIOCHEMICAL PHARMACOLOGY
- Role of homologous recombination in trabectedin-induced DNA damage
- (2008) M. Tavecchio et al. EUROPEAN JOURNAL OF CANCER
- Transcription-coupled DNA Double-Strand Breaks Are Mediated via the Nucleotide Excision Repair and the Mre11-Rad50-Nbs1 Complex
- (2008) Josée Guirouilh-Barbat et al. MOLECULAR BIOLOGY OF THE CELL
- Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers
- (2008) E. V. Stevens et al. MOLECULAR CANCER THERAPEUTICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started